Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 16/382,446, filed Apr 12, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,737,972 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles In force · Medium confidence | Crititech, Inc. | In force | Medium confidence | ||
| US 12,128,131 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles In force · Low confidence | Crititech, Inc. | In force | Low confidence | ||
| US 11,523,983 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles In force · Medium confidence | Crititech, Inc. | In force | Medium confidence | ||
| Application 16/382,446 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles Abandoned Abandoned Jun 11, 2021 | Crititech, Inc. | Abandoned | Abandoned Jun 11, 2021 | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Crititech, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.